Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem PPA insurance dispute

This article was originally published in The Tan Sheet

Executive Summary

Kemper Indemnity Insurance is asking a Chattanooga federal court to rescind a $50 mil. excess product liability insurance policy issued to Chattem. In a July 31 lawsuit, Kemper alleges the Dexatrim marketer failed to disclose the preliminary results of the Hemorrhagic Stroke Project study on phenylpropanolamine during "the submission process to renew the Kemper policy for coverage for the Dec. 21, 1999 to May 31, 2001 policy period," Chattem says in an Aug. 13 press release. Alternatively, Kemper is seeking a declaratory judgment to bar or limit coverage of PPA claims. Chattem says the Kemper policy provides coverage "in excess of $23.5 mil. of product liability insurance" available from two other insurers. Chattem, which is a defendant in approximately 155 PPA suits related to its sale of Dexatrim, said the Kemper claims are meritless and it may file a counterclaim against the insurer for bad faith...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel